I tested these GLP-1 programs against the questions buyers actually ask after the ads stop helping: What does it cost, who reviews the intake, where does the medication come from, and what happens after the first shipment?
Here is where things actually stand now, ranked by what I think matters most for the average person paying out of pocket.
1. HealthRX
Price and pharmacy transparency together in one place. That combination is rarer than it sounds.
HealthRX runs a straightforward telehealth model: fill out a health assessment online, a U.S. board-certified physician reviews it within roughly 24 hours, and medication ships overnight at no extra charge to all 50 states. Compounded semaglutide starts at $99 per month. Compounded tirzepatide starts at $149 per month. Those are among the lowest cash prices I have found for either compound from a provider that actually names its pharmacy.
That pharmacy is Manifest Pharmacy in Greer, South Carolina, a 503A compounding facility operating under USP-797 standards with lot-tracked batches from production through delivery. HealthRX also carries LegitScript certification (certificate 50087439), which requires ongoing review. Most discount-adjacent compounders skip that step.
The clinical reference points are trial data, not proprietary claims. Tirzepatide produced roughly 21% average body weight reduction over 72 weeks in the SURMOUNT-1 trial. Semaglutide produced roughly 15% over 68 weeks in STEP 1. HealthRX points to those numbers without inflating them.
One honest caveat: these are compounded medications, not FDA-approved finished products. That is true of most cash-pay telehealth options right now, and worth understanding before you commit.
Best for: cash-pay patients who want low monthly pricing, confirmed overnight shipping nationwide, and a named 503A pharmacy they can actually look up.
2. FormBlends
FormBlends is the right fit for a particular type of buyer. Someone who wants published analytical testing, not just a statement that testing was done.
The platform dispensed compounded GLP-1s through an FDA-registered 503A pharmacy, with per-product documentation that includes HPLC purity percentages, mass spec identity confirmation, and endotoxin and sterility results. Those numbers are published. That level of transparency is not standard among GLP-1 telehealth providers.
Pricing is higher than HealthRX. Semaglutide comes in at roughly $299 per vial and tirzepatide at roughly $349. Shipping covers 47 states, not all 50. Physician oversight is part of the model.
What makes FormBlends genuinely different from almost every other provider on this list is the broader catalog. Alongside the GLP-1 options, it carries peptides for recovery, longevity, and cognitive support under the same clinician-supervised structure. If you are already interested in a wider protocol and want one provider for all of it, this is the only option here that does that.
Best for: buyers who want purity documentation they can read, or who want GLP-1 treatment alongside a broader peptide program from a single provider.
3. Mochi Health
Mochi Health built its reputation on having actual obesity-medicine board-certified clinicians reviewing cases, not just general practitioners clearing prescriptions. Compounded semaglutide runs around $99 per month and compounded tirzepatide around $199. The monitoring is more structured than most budget options, which matters for people who want clinical check-ins built in.
Good middle ground between price and oversight.
Best for: patients who want more than a quick prescription, with obesity-specialist review baked into the process.
4. Ro Body
Ro has a prior-authorization team that works with insurance for branded GLP-1 medications, which is genuinely useful if you have coverage and the patience for that process. The membership starts at $39 for the first month, then $74 to $149 monthly, with medications billed separately. Ro exited compounded semaglutide after the March 2026 regulatory shift and now focuses on branded options.
If insurance is part of your plan, Ro is worth a serious look.
Best for: insured patients chasing prior auth for branded Wegovy or Zepbound, who want a platform that handles the paperwork side.
5. Hims & Hers
Hims & Hers is now on branded medications following the March 2026 Novo settlement. Injectable Wegovy runs around $299 per month through the platform. Zepbound is around $399. Oral semaglutide is around $249. With insurance plus a savings card, some users have brought that down to $0 to $25 monthly. The brand is large, the app is polished, and the pharmacy infrastructure is established.
The catch is that without insurance, these prices are not competitive with cash-pay compounded options.
Best for: patients with insurance or savings card eligibility who prefer a brand-name product and a well-known platform.
6. Henry Meds
Henry Meds is quick. Compounded GLP-1 medications ship in 24 to 72 hours and pricing for the first month runs $179 to $249. It is a cash-pay model. The monitoring and coaching layers are lighter than Mochi or Ro, so this is a better fit for someone who already understands the medication and wants the simplest, fastest path to a prescription and shipment.
Best for: people who have done their research, do not need heavy clinical hand-holding, and just want fast, affordable access.
Quick Comparison
| Provider | Sema Price (approx.) | Tirz Price (approx.) | Ships To | Pharmacy Type |
| HealthRX | $99/mo | $149/mo | All 50 states | Named 503A (Manifest, SC) |
| FormBlends | ~$299/vial | ~$349/vial | 47 states | FDA-registered 503A |
| Mochi Health | ~$99/mo | ~$199/mo | Most states | Compounded |
| Ro Body | Branded meds | Branded meds | Most states | Branded pharmacy |
| Hims & Hers | ~$249 oral / $299 inj | ~$399 (Zepbound) | Most states | Branded pharmacy |
| Henry Meds | ~$179-249 mo 1 | Varies | Most states | Compounded |
FAQ
Are compounded GLP-1 medications the same thing as Ozempic or Wegovy?
No. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products. They are prepared by compounding pharmacies and are not identical to branded medications in terms of regulatory status. The active ingredient may be the same, but the formulation, inactive components, and oversight pathway differ.
Why did so many platforms change their offerings in early 2026?
Novo Nordisk reached a settlement in March 2026 that prompted several telehealth companies to stop selling compounded semaglutide. The FDA also issued warning letters to more than 30 firms around the same period. The overall direction is toward branded products, though compounded options remain available through 503A pharmacies under current rules.
What should I look for in a compounding pharmacy?
At minimum: 503A registration, USP-797 compliance for sterile injectables, and some form of third-party credentialing or lot-level testing. A pharmacy that is named and publicly verifiable is always better than one described only as a “partner lab.”
Does insurance cover GLP-1 medications through these platforms?
Some platforms, including Ro and Hims & Hers, work with insurance for branded medications. Cash-pay compounded options like HealthRX and Henry Meds do not bill insurance. Manufacturer savings cards can significantly reduce out-of-pocket cost for branded products if you qualify.
How fast do results typically happen?
Individual results vary widely and depend on starting weight, adherence, diet, and other factors. Clinical trial data for semaglutide showed roughly 15% body weight reduction over 68 weeks at full therapeutic dosing. Tirzepatide showed roughly 21% over 72 weeks in SURMOUNT-1. Expect months, not weeks, for meaningful change at therapeutic doses.
Sources
- FDA compounding guidance and 503A pharmacy regulations, FDA.gov
- SURMOUNT-1 trial results, published in the New England Journal of Medicine (2022)
- STEP 1 trial results, published in the New England Journal of Medicine (2021)
- LegitScript pharmacy certification program, LegitScript.com
- Novo Nordisk settlement reporting, Reuters and STAT News (March 2026)
- Lilly orforglipron launch pricing, LillyDirect and Lilly investor communications (April 2026)
